U
ACHN

UBS’s Achillion Pharmaceuticals ACHN Stock Holding History

UBS’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2.01M Buy
201,372
+127,235
+172% +$1.18M ﹤0.01% 2909
2014
Q2 		$562K Buy
74,137
+15,965
+27% +$63.7K ﹤0.01% 4110
2014
Q1 		$191K Buy
58,172
+25,567
+78% +$89.5K ﹤0.01% 5241
2013
Q4 		$108K Buy
32,605
+27,637
+556% +$80.2K ﹤0.01% 5989
2013
Q3 		$15K Sell
4,968
-1,282
-21% -$8.79K ﹤0.01% 8418
2013
Q2 		$51K Buy
+6,250
New +$47.7K ﹤0.01% 6715

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UBS's ACHN Position: Q3 2014 in Review

UBS increased its Achillion Pharmaceuticals (ACHN) stake by 172% in Q3 2014, buying an estimated $1.18M and bringing the position to 201,372 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2909.

UBS first reported a position in ACHN in Q2 2013 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold ACHN as of Q3 2014.

  • UBS held 201,372 shares of Achillion Pharmaceuticals worth $2.01M as of Q3 2014.
  • UBS bought 127,235 Achillion Pharmaceuticals shares in Q3 2014, an estimated $1.18M.
  • Achillion Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2909 holding.
  • UBS first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.